Skip to main content
 

Medium.com: Editing the Software of Life, for Fame and Fortune

June 18, 2015

On a fall day in 2011, Jennifer Doudna was in her office at the University of California, Berkeley, chatting with one of her graduate students. She and the student, Rachel Haurwitz, had been investigating a seemingly arcane topic — how bacteria fend off invading viruses. They had homed in on a particularly interesting family of bacterial proteins, and were starting to dream a little.

FierceBiotech: The 25 most influential people in biopharma in 2015

May 13, 2015

Scientists rarely make their way into the industry limelight. Years spent in the lab patiently laboring toward a breakthrough often involves painstaking effort building on the work of others. And even the most brilliant investigators tend to be on the sidelines when the plaudits are handed out to the clinical-stage developers and marketing gurus that capitalize on their advances.

The New York Times: Jennifer Doudna, a Pioneer Who Helped Simplify Genome Editing

May 11, 2015

As a child in Hilo, one of the less touristy parts of Hawaii, Jennifer A. Doudna felt out of place. She had blond hair and blue eyes, and she was taller than the other kids, who were mostly of Polynesian and Asian descent.
 

TIME: The 100 Most Influential People

April 16, 2015

No one, not even a bacterium, likes being infected by a virus, and early in evolution, bacteria developed a way to destroy viruses with exquisitely precise attacks. Very recently, Emmanuelle Charpentier and Jennifer Doudna figured out the inner workings of this bacterial self-protection, and then, in a tour de force of elegant deduction and experiment, they developed a plug-and-play version of that approach.

Xconomy: Doudna’s Caribou Bio Raises $11M To Expand Uses For Gene Editing Tech

April 2, 2015

Caribou Biosciences, one of the biotech startups working to advance a much-watched new technology for precise gene editing, announced today it has raised an $11 million Series A round from venture capital firms and Swiss drug giant Novartis.

Pages